Company
CSL
CSL has 52 drugs tracked on RxWires: 10 post-market, 20 in Phase 3, 2 in Phase 2/3, 10 in Phase 2, 1 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Blood coagulation Factor VIII and vWF, human | Post-Market | Von Willebrand Disease |
| Garadacimab | Post-Market | Hereditary Angioedema |
| CE1226 | Post-Market | Alpha1 Antitrypsin Deficiency |
| Voncento | Post-Market | Von Willebrand Disease |
| RiaSTAP | Post-Market | Coagulopathic Bleeding |
| Subcutaneous Immune Globulin (Human) (Hizentra) | Post-Market | Primary Immune Deficiency |
| four factor prothrombin complex concentrate | Post-Market | Anticoagulation |
| IgPro | Post-Market | Primary Immunodeficiency |
| Alpha1-proteinase inhibitor | Post-Market | Alpha1-proteinase Inhibitor Deficiency |
| Vivaglobin | Post-Market | Common Variable Immunodeficiency |
| FXIII Concentrate (Human) (FXIII) | Phase 3 | Factor XIII Deficiency |
| CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) | Phase 3 | Hemophilia B |
| IgPro20 | Phase 3 | Secondary Immune Deficiency |
| CSL511 Fibrinogen concentrate (human) | Phase 3 | Acquired Fibrinogen Deficiency |
| Recombinant single-chain factor VIII (rVIII-SingleChain) | Phase 3 | Congenital Hemophilia A |
| CSL312 | Phase 3 | Hereditary Angioedema |
| Alpha-1 antitrypsin (AAT) | Phase 3 | Graft Versus Host Disease (GVHD) |
| Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) | Phase 3 | Hemophilia B |
| IgNextGen 16% | Phase 3 | Primary Immunodeficiency (PID) |
| Immunoglobulin G (Ig NextGen 16%) | Phase 3 | Primary Immune Deficiency |
| rIX-FP | Phase 3 | Hemophilia B |
| Human Normal Immunoglobulin for Subcutaneous Administration | Phase 3 | Primary Immune Deficiency |
| C1-esterase inhibitor | Phase 3 | Antibody-mediated Rejection |
| BE1116 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass |
| Privigen (Human normal immunoglobulin G (IgG > 98 % purity)) | Phase 3 | Kidney Transplantation |
| rVIII-SingleChain | Phase 3 | Congenital Hemophilia A |
| AAV5-hFIXco-Padua | Phase 3 | Hemophilia B |
| Immunoglobulins Intravenous (Human) | Phase 3 | Agammaglobulinemia |
| Biostate | Phase 3 | Hemophilia A |
| Beriplex® P/N (Kcentra) | Phase 3 | Blood Coagulation Disorders |
| CSL300 | Phase 2/3 | End Stage Kidney Disease |
| AAT | Phase 2/3 | Acute-graft-versus-host Disease |
| CSL787 | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| Vamifeport | Phase 2 | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis |
| CSL889 | Phase 2 | Sickle Cell Disease Vaso-occlusive Crisis |
| Anumigilimab | Phase 2 | Sickle Cell Disease |
| CSL346 | Phase 2 | Diabetic Kidney Disease (DKD) |
| Alpha-proteinase inhibitor | Phase 2 | Eosinophilic Esophagitis |
| ALD518 | Phase 2 | Oral Mucositis |
| BMS-945429 | Phase 2 | Arthritis, Psoriatic |
| Fibrogammin®P, coagulation factor XIII concentrate (Human) | Phase 2 | Systemic Sclerosis |
| CSL324 | Phase 2 | Coronavirus Disease 2019 (COVID-19) |
| C1-esterase inhibitor - single intravenous dose | Phase 1/2 | Hereditary Angioedema Types I and II |
| Vamifeport IRF | Phase 1 | Healthy Volunteers |
| Recombinant Coagulation Factor IX Albumin Fusion Protein | Phase 1 | Hemophilia B |
| Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 | Phase 1 | Anemia, Sickle Cell |
| CSL760 | Phase 1 | Coronavirus Disease 2019 (COVID-19) |
| CSL362 | Phase 1 | Leukemia, Myeloid, Acute |
| CSL730 | Phase 1 | Healthy |
| Eptacog alfa (activated) or pdFVII | Phase 1 | Congenital Coagulation Factor VII Deficiency |
| Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody | Phase 1 | Hidradenitis Suppurativa |
| SQ IVIG | Not Applicable | Infections After Lung Transplant |
Latest
No recent events.
Follow CSL on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.